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Hydrogen gas is a bioactive molecule that has a diversity of effects, including anti-apoptotic, anti-inflammatory and
anti-oxidative properties; these overlap with the process of neuroprogression in major psychiatric disorders.
Specifically, both bipolar disorder and schizophrenia are associated with increased oxidative and inflammatory
stress. Moreover, lithium which is commonly administered for treating bipolar disorder has effects on oxidative
stress and apoptotic pathways, as do valproate and some atypical antipsychotics for treating schizophrenia.
Molecular hydrogen has been studied pre-clinically in animal models for the treatment of some medical conditions
including hypoxia and neurodegenerative disorders, and there are intriguing clinical findings in neurological
disorders including Parkinson’s disease. Therefore, it is hypothesized that administration of hydrogen molecule may
have potential as a novel therapy for bipolar disorder, schizophrenia, and other concurrent disorders characterized
by oxidative, inflammatory and apoptotic dysregulation.Introduction
Normally, there is a balance between oxidant and anti-
oxidant systems in body. When there is an imbalance
between anti-oxidative defenses and prevailing oxidative
stress, reactive oxidative species are increased leading to
inflammation and oxidative damage marked by protein
carbonylation, DNA damage [1,2] and lipid peroxidation.
These biomarkers are documented in all illness phases,
but appear more pronounced in episodes of acute illness,
particularly mania [3].
Bipolar mood disorder is a relatively common neuro-
psychiatric disorder with an estimated prevalence of 1%
to 2% [4], and a high burden of disease [4]. There is a
high rate of medical comorbidity including diabetes and
the metabolic syndrome [5], cardiovascular morbidity
[6], and obesity [7], all of which are associated with in-
flammatory changes and oxidative stress. These comor-
bidities lead to a novel hypothesis that bipolar disorder
is a part of a multi-system inflammatory process [8].* Correspondence: ghanizad@sina.tums.ac.ir
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distribution, and reproduction in any mediumAdditionally, schizophrenia has a point prevalence of
3.59/1000 in general population [9]. The mean Canadian
rates is 25.9 (S.D. = 10.5) per 100,000 [10]. Schizophrenia
is also comorbid with medical conditions such as diabetes
(adjusted OR: 2.11 (1.36 to 3.28) [11], overweight or obes-
ity (44%) [12] and cardiovascular events [13]. Schizophre-
nia as well as bipolar disorder are part of a multisystem
inflammatory processes [14] and anti-inflammatory ther-
apy for treating schizophrenia is suggested [15].Mitochondria and bipolar mood disorder
Mitochondria are necessary for the generation of energy
and synaptic signaling. Mitochondrial dysfunction ap-
pears to be involved in the pathophysiology of bipolar
disorder [16]. The prevalence of bipolar disorder in
patients with mitochondrial cytopathies is higher than
among healthy controls [17]. Reduction in complex one
activity of the mitochondrial electron transport chain is
documented [18], and there are intriguing preliminary
electron microscopy reports of mitochondrial ultrastruc-
tural changes in the disorder, particularly abnormal per-
ipheral clustering of mitochondrial in the cytosol [19].
Mitochondrial DNA deletions are increased [20]. Mito-
chondrial dysfunction has thus been hypothesizes as aCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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that novel therapeutic agents for treating bipolar mood
disorder should target mitochondrial function [16].
Bipolar disorder and oxidative stress
The generation of oxidatively generated free radicals is
core to life, and is normally tightly controlled. However,
there is now increasing data on the presence and impact
of oxidative stress among diverse psychiatric disorders
including bipolar disorder [22], schizophrenia, and au-
tism [23,24]. Reactive oxygen species (ROS) production
and metabolism appears to play an important role in the
pathophysiology of bipolar disorder [22,25,26]. Not only
are both total glutathione and reduced glutathione le-
vels, which are core parts of the intrinsic anti-oxidative
system decreased in bipolar disorder, but antioxidant en-
zyme activities are also impaired [22]. Levels of key
redox enzymes including SOD and catalase have been
reported to be lower in patients with bipolar disorder
than in matched controls [27]. Nitrous oxide (NO) is im-
plicated in the generation of psychotic symptoms such
as delusions in bipolar disorder [28]. A meta-analysis
reported that the level of NO appears to be significantly
increased in bipolar disorder [29]. Moreover, the level
of thiobarbituric acidic reactive substances (TBARS), a
marker of lipid peroxidation through reaction between
free radicals and lipid structures, is increased during
manic episodes and remission [30,31]. This finding sug-
gests that oxidative damage to lipid structures is pro-
bably continued during the course of bipolar disorder.
Mechanism of action of established therapies
Lithium is arguably the most effective medication for the
prevention of long-term relapse in bipolar mood dis-
order [32,33]. Lithium’s effects extend beyond its mode
of action of monoamine receptors [34]. Chronic treat-
ment with lithium leads to mitochondrial proteins phos-
phorylation in the rat prefrontal cortex [34]. Lithium
also has effects through its impact on inflammation and
by the prevention of oxidative stress and cytokine chan-
ges [35]. These anti-inflammatory and antioxidative ef-
fects are potentially neuroprotective [36,37]. Lithium
increases mitochondrial respiratory chain enzyme ac-
tivities, particularly complex 1, that may be linked to
its therapeutic efficacy [38]. Lithium increases mito-
chondrial energy production [38]. Decreased Na(+)-K
(+)-ATPase activity and increased lipid peroxidation in
that are seen in bipolar disorder may improve following
lithium administration [39]. Long term lithium admi-
nistration enhances anti-oxidative defenses in bipolar
disorder [40] as well as in healthy individuals [41].
N-acetyl-cysteine (NAC), a glutathione based redox mo-
dulator, anti-inflammatory agent and mitochondrial mo-
dulator [42] decreases symptoms of depression and mania[43] in bipolar disorder [44]. However, established agents
have tolerability issues and efficacy limitations, therefore
more novel therapeutic approached are needed.
Mitochondria and schizophrenia
Mitochondrial dysfunction in schizophrenia is frequently
reported [45]. Moreover, mitochondrial disorders can
present with psychosis [46]. mtDNA plays a role in the
neurobiology of schizophrenia [47]. Mitochondrial gene
expression is changed in schizophrenia [48]. The numbers
of mitochondria in schizophrenia is reduced compared to
normal controls [49]. This change in mitochondria may
be associated with differential responsiveness to treatment
[50]. However, it is not clear whether this number is adap-
tive or an etiological link to this disorder [51]. More-
over, mitochondrial energy production is impaired in
autism [52].
Schizophrenia and oxidative stress
The role oxidative stress in the neurobiology of schizo-
phrenia is a promising target in order to provide new
therapeutic interventions [53]. This is grounded on data
that the antioxidant defense system is impaired in schi-
zophrenia [54]. In comparison to normal controls, the
activities of superoxide dismutase (SOD), glutathione
peroxidase (GSH-Px) are decreased while the levels of
MDA are increased chronic schizophrenia [55]. Reduced
cellular respiration and complex I abnormalities in schi-
zophrenia are a possible endophenotypic biomarker for
schizophrenia [56]. Furthermore, the severity of neuro-
logical soft signs in patients with schizophrenia is asso-
ciated with the level of decreased superoxide dismutase
activity [57]. Treatment refractory schizophrenia is asso-
ciated with higher lipid peroxidation [58].
Mechanism of action of antipsychotics
The increase of plasma lipid peroxidation in schizophre-
nia is not due to second-generation antipsychotics [59].
But both typical and atypical antipsychotic medication
partially normalize abnormal free radical metabolism in
schizophrenia [60]. Long term treatments with both ty-
pical and atypical antipsychotics have effects on antioxi-
dant enzymes and lipid peroxidation in schizophrenia
[55]. Supplementation of vitamin C with atypical decrea-
ses oxidative stress in schizophrenia [61]. N actylcys-
teine, a redox modulator and glutamate modulator,
reduces core symptoms and akathisia in schizophrenia,
providing a preliminary proof of concept for the role of
oxidative pathways [62].
Pharmacokinetics of Hydrogen
Molecular hydrogen is an odourless and tasteless gas
that has the ability to rapidly diffuse through lipid mem-
branes and enter the cell, where it easily penetrates
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It is inert at room temperature and in the absence of
catalysts. It additionally easily crosses the blood brain
barrier, which facilitates access to the target organs and
subcellular components. Its adverse event profile is re-
portedly benign [2,63]. Physiologically, hydrogen is pro-
duced by intestinal microbiota from fermentation of
complex carbohydrates. Arterial blood contains higher
levels of hydrogen that tissue, suggesting some uptake
and utilization of hydrogen in tissues. Hydrogen reacts
with free hyrodoxyl radicals but does not appear to react
to other reactive oxygen species. This is a theoretical
advantage, as low levels of these radicals have physio-
logically relevant signaling effects. It protects against
secondary oxidative damage to the brain in a variety of
models by reacting with hydroxyl radicals [64]. Hydro-
gen is potentially available as a medical gas, hydrogen
enriched water, taking a hydrogen bath, injecting hydro-
gen saline, hydrogen saline eye drops, and augmenting
bacterial production of intestinal hydrogen. It penetrates
glass but not aluminum containers.Hydrogen and oxidative stress and inflammation
Anti-inflammatory effects of hydrogen molecule have
been reported in both animal and human models. Hy-
drogen-rich saline decreases the levels of cytokines IL-4,
IL-5, IL-13 and TNF-α in bronchoalveolar lavage fluid
[65]. Its effects on tumor necrosis factor alpha, interleu-
kin (IL)-1β and IL-6 levels is hypothesized as the reason
for its protective role against UVB radiation [66]. Hydro-
gen molecule also stops TNFα-induced activation of the
NFκB pathway [67]. Hydrogen released by intestinal
microbiota, such a hydrogen producing strain of E. coli
can suppress inflammation [68]. Taken together, these
findings are germane to bipolar disorder as current evi-
dences implicates many interleukins in the neurobiology
of bipolar disorder [69].Preclinical findings
Inhalation of hydrogen decreased acute lung inflam-
mation in an animal model of acute lung injury [70,71].
Hydrogen enriched water decreased the production of
reactive oxygen species in the rat kidney [72]. It protects
mitochondria and nuclear DNA from hydroxyl radicals,
preventing the decline in mitochondrial membrane
potential after antimycin treatment. It has potential in
preventing ionizing radiation induced damage, as hy-
droxyl radicals are the major vehicle for secondary da-
mage. Hydrogen reduces infarction size in a model of
middle cerebral artery occlusion and reduced oxidative
stress markers [73]. In asphyxiated newborn piglets, it is
similarly neuroprotective and preserves cerebrovascular
reactivity [74].Clinical findings
Hydrogen is hypothesized as a potential therapy for differ-
ent oxidative stress related diseases such as Parkinson's
disease; ischemia/reperfusion of spinal cord, heart, lung,
liver, kidney, and intestine; transplantation of lung, heart,
kidney, and intestine [75], and autism [76,77]. Adequate
hydration with hydrogen-rich water decreases blood
lactate levels and improved function of muscle in ath-
letes [78].
Among participants with type 2 diabetes, hydrogen re-
duced levels of oxidative stress markers [68], and similar
findings are reported in the metabolic syndrome [79]. In
Parkinson’s disease, increased oxidative stress indexed by
elevated lipid peroxidation and decreased reduced glu-
tathione levels in the substantia nigra are part of the
known pathogenesis of PD. Hydrogen water also pre-
vents a rat model of Parkinson’s disease [80] and increa-
ses survival after cerebral ischemia/reperfusion [81,82].
It down-regulates 4-hydroxy-2-nonenal, a marker of oxi-
dative stress in dopaminergic neurons within the subs-
tantia nigra of animal models of Parkinson’s disease. A
preclinical study failed to find any association between
response to hydrogen and dose [37]. In a pilot placebo
controlled, randomized, double-blind, parallel-group de-
sign (N = 18), the efficacy of 1000ml molecular hydrogen
daily was investigated in patients taking levodopa. In the
hydrogen group, there was a reduction in Total Unified
Parkinson’s Disease Rating Scale scores, whereas the pla-
cebo group deteriorated [83]. Signal modulating activi-
ties of hydrogen may play a role in exerting a protective
effect against Parkinson’s [79].
It is not fully understood how hydrogen plays its puta-
tive antioxidative or anti-inflammatory role. However, it
may regulate particular metalloproteins [84]. Moreover,
hydrogen reduces the production of peroxynitrite de-
rived from nitric oxide [85]. In patients with rheumatoid
arthritis, drinking of water enriched with hydrogen was
shown to decreases oxidative stress through scavenging
hydroxyl radical and also decreases clinical symptoms
after 4 weeks [86]. Moreover, hydrogen-enriched water
improves quality of life of patients with liver cancer after
radiation exposure [87].
Intravenous administration of 500 ml of H2 enriched
fluid has also been examined and it decreased the symp-
toms of 4 patients with acute erythematous skin diseases
with fever and/or pain [88]. A randomized controlled
trial indicated that hydrogen-enriched water decreased
mitochondrial dysfunction and inflammation in patients
with mitochondrial myopathies [89].
Caveats are however necessary, inasmuch as orally ad-
ministered hydrogen-enriched water may not have enough
molecular hydrogen to adequately scavenge hydroxyl radi-
cals. Secondly, the dwell time of hydrogen in the body
may be too short to scavenge substantial quantities of
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the optimal frequency, dosage, and its method of adminis-
tration for different diseases are not studied [75].
Conclusions
Hydrogen gas has a number of biological properties that
make it an appealing candidate agent for a diversity of
disorders sharing inflammatory, oxidative and apoptotic
mechanisms. However, a number of caveats are neces-
sary. Administration is complex, aggravated by its very
short biological half-life and low saturation point of
0,8 mM. Furthermore, the low dose used in many stu-
dies (0.04-0.08 mM) is shadowed by the fact that intes-
tinal microbiota produce up to 1L a day of hydrogen
[91]. There is currently very a limited understanding of
the pathways and processes impacted by hydrogen.
Greater preclinical data is required to elucidate the bio-
logical mechanisms of hydrogen. It however is true that
many agents are in widespread use despite poor under-
standing of their mechanisms of action, particularly in
the neurosciences. This therefore does not preclude use,
which is therefore far more contingent on safety issues.
Given that hydrogen does seem to have a benign safety
profile, albeit based on very limited data, moving to cli-
nical studies appears warranted. We additionally need
a more complete understanding of hydrogen’s dosage,
mode of administration, pharmacokinetics, biology and
toxicity of hydrogen to facilitate clinical application. Ne-
vertheless, there is much that is appealing about this
avenue, and it merits greater investment given the pau-
city of therapeutic options and their limitations.
Competing interests
AG has no related conflict of interest to be declared. MB has received Grant/
Research Support from the NIH, Cooperative Research Centre, Simons Autism
Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation,
MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research
Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon,
Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca,
Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck,
Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant
to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag,
Lundbeck Merck and Servier, and is a co-inventor of two provisional patents
regarding the use of NAC and related compounds for psychiatric indications,
which, while assigned to the Mental Health Research Institute, could lead to
personal remuneration upon a commercialization event.
Authors’ contributions
AG was responsible for the initial conception and drafting of the manuscript.
AG and MB revised the preliminary draft of the manuscript. Both authors
read and approved the final manuscript.
Author details
1Research Center for Psychiatry and Behavioral Sciences, Shiraz University of
Medical, Sciences, Hafez Hospital, Shiraz, Iran. 2Department of Psychiatry,
Hafez Hospital, School of Medicine, Shiraz University of Medical Sciences,
Shiraz, Iran. 3School of Medicine, Deakin University, Melbourne, Australia.
4The Florey Institute of Neuroscience and Mental Health, Orygen Research
Centre, University of Melbourne, 234 St Kilda Rd, Southbank VIC 3006,
Australia. 5The Department of Psychiatry, University of Melbourne, 234 St
Kilda Rd, Southbank, VIC 3006, Australia.Received: 13 December 2012 Accepted: 30 May 2013
Published: 6 June 2013
References
1. Andreazza AC, et al: Specific subcellular changes in oxidative stress in
prefrontal cortex from patients with bipolar disorder. J Neurochem 2013
[Epub ahead of print].
2. Soeiro-de-Souza MG, et al: Number of manic episodes is associated with
elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol
2013:1–8 [Epub ahead of print].
3. Frey BN, et al: Biomarkers in bipolar disorder: a positional paper from the
International Society for Bipolar Disorders Biomarkers Task Force. Aust N
Z J Psychiatry 2013, 47(4):321–32.
4. Fagiolini A, et al: Prevalence, chronicity, burden and borders of bipolar
disorder. J Affect Disord 2013, 148(2–3):161–9.
5. Bai YM, et al: Risk of developing diabetes mellitus and hyperlipidemia
among patients with bipolar disorder, major depressive disorder, and
schizophrenia: A 10-year nationwide population-based prospective
cohort study. J Affect Disord 2013 [Epub ahead of print].
6. Callaghan RC, Khizar A: The incidence of cardiovascular morbidity among
patients with bipolar disorder: a population-based longitudinal study in
Ontario. Canada. J Affect Disord 2010, 122(1–2):118–23.
7. Gurpegui M, et al: Overweight and obesity in patients with bipolar
disorder or schizophrenia compared with a non-psychiatric sample. Prog
Neuropsychopharmacol Biol Psychiatry 2012, 37(1):169–75.
8. Leboyer M, et al: Can bipolar disorder be viewed as a multi-system
inflammatory disease? J Affect Disord 2012, 141(1):1–10.
9. Shivashankar S, et al: Has the prevalence, clinical presentation and social
functioning of schizophrenia changed over the last 25 years? Nithsdale
schizophrenia survey revisited. Schizophr Res 2013, 146(1–3):349–56.
10. Dealberto MJ: Are the rates of schizophrenia unusually high in Canada?
A comparison of Canadian and international data. Psychiatry Res 2013
[Epub ahead of print].
11. Carney CP, Jones LE: Medical comorbidity in women and men with
bipolar disorders: a population-based controlled study. Psychosom Med
2006, 68(5):684–91.
12. Guo X, et al: The relationship between obesity and neurocognitive
function in Chinese patients with schizophrenia. BMC Psychiatry 2013,
13:109.
13. Protopopova D, et al: The prevalence of cardiometabolic risk factors and
the ten-year risk of fatal cardiovascular events in patients with
schizophrenia and related psychotic disorders. Psychiatr Danub 2012,
24(3):307–13.
14. Falcone T, et al: Does systemic inflammation play a role in pediatric
psychosis. Clin Schizophr Relat Psychoses 2013:1–43 [Epub ahead of print].
15. Muller N, et al: Anti-inflammatory treatment in schizophrenia.
Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:146–53.
16. Kato T: The role of mitochondrial dysfunction in bipolar disorder.
Drug News Perspect 2006, 19(10):597–602.
17. Fattal O, et al: Psychiatric comorbidity in 36 adults with mitochondrial
cytopathies. CNS Spectr 2007, 12(6):429–38.
18. Scola G, et al: A fresh look at complex I in microarray data: clues to
understanding disease-specific mitochondrial alterations in bipolar
disorder. Biol Psychiatry 2013, 73(2):e4–5.
19. Cataldo AM, et al: Abnormalities in mitochondrial structure in cells from
patients with bipolar disorder. Am J Pathol 2010, 177(2):575–85.
20. Kato T, et al: Increased levels of a mitochondrial DNA deletion in the
brain of patients with bipolar disorder. Biol Psychiatry 1997, 42(10):871–5.
21. Kato T: Mitochondrial dysfunction as the molecular basis of bipolar
disorder: therapeutic implications. CNS Drugs 2007, 21(1):1–11.
22. Raffa M, et al: Reduced antioxidant defense systems in schizophrenia
and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012,
39(2):371–5.
23. Ghanizadeh A, et al: Glutathione-related factors and oxidative stress in
autism, a review. Curr Med Chem 2012, 19(23):4000–5.
24. Ghanizadeh A: Gold nanoparticles and lipoic acid as a novel anti-
inflammatory treatment for autism, a hypothesis. Journal of Medical
Hypotheses and Ideas 2012, 6(1):40–43.
25. Kulak A, et al: Redox dysregulation in the pathophysiology of
Schizophrenia and bipolar disorder: insights from animal models.
Antioxid Redox Signal 2012, 18(12):1428–43.
Ghanizadeh and Berk Medical Gas Research 2013, 3:11 Page 5 of 6
http://www.medicalgasresearch.com/content/3/1/1126. Steckert AV, et al: Role of oxidative stress in the pathophysiology of
bipolar disorder. Neurochem Res 2010, 35(9):1295–301.
27. Ranjekar PK, et al: Decreased antioxidant enzymes and membrane
essential polyunsaturated fatty acids in schizophrenic and bipolar mood
disorder patients. Psychiatry Res 2003, 121(2):109–22.
28. Gergerlioglu HS, et al: Changes in nitric oxide level and superoxide
dismutase activity during antimanic treatment. Prog
Neuropsychopharmacol Biol Psychiatry 2007, 31(3):697–702.
29. Andreazza AC, et al: Oxidative stress markers in bipolar disorder: a
meta-analysis. J Affect Disord 2008, 111(2–3):135–44.
30. Andreazza AC, et al: Serum S100B and antioxidant enzymes in bipolar
patients. J Psychiatr Res 2007, 41(6):523–9.
31. Frey BN, et al: Increased oxidative stress and DNA damage in bipolar
disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry
2007, 31(1):283–5.
32. Geddes JR, Miklowitz DJ: Treatment of bipolar disorder. Lancet 2013,
381(9878):1672–82.
33. Malhi GS, et al: Potential mechanisms of action of lithium in bipolar
disorder. Current understanding. CNS Drugs 2013, 27(2):135–53.
34. Corena-McLeod M, et al: New model of action for mood stabilizers:
phosphoproteome from rat pre-frontal cortex synaptoneurosomal
preparations. PLoS One 2013, 8(5):e52147.
35. Albayrak A, et al: Protective effects of lithium: A new look at an old drug
with potential antioxidative and anti-inflammatory effects in an animal
model of sepsis. Int Immunopharmacol 2013, 16(1):35–40.
36. Chiu CT, et al: Therapeutic potential of mood stabilizers lithium and
valproic acid: beyond bipolar disorder. Pharmacol Rev 2013, 65(1):105–42.
37. Yu F, et al: Lithium ameliorates neurodegeneration, suppresses
neuroinflammation, and improves behavioral performance in a mouse
model of traumatic brain injury. J Neurotrauma 2012, 29(2):362–74.
38. Maurer IC, Schippel P, Volz HP: Lithium-induced enhancement of
mitochondrial oxidative phosphorylation in human brain tissue. Bipolar
Disord 2009, 11(5):515–22.
39. Banerjee U, et al: Effects of lithium therapy on Na + −K + −ATPase activity
and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol
Psychiatry 2012, 37(1):56–61.
40. Arraf Z, et al: Lithium and oxidative stress lessons from the MPTP model
of Parkinson’s disease. Neurosci Lett 2012, 516(1):57–61.
41. Khairova R, et al: Effects of lithium on oxidative stress parameters in
healthy subjects. Mol Med Report 2012, 5(3):680–2.
42. Samuni Y, et al: The chemistry and biological activities of N-
acetylcysteine. Biochim Biophys Acta 2013, 1830(8):4117–4129.
43. Magalhaes PV, et al: A preliminary investigation on the efficacy of N-acetyl
cysteine for mania or hypomania. Aust N Z J Psychiatry 2013, 47(6):564–8.
44. Berk M, et al: N-acetyl cysteine for depressive symptoms in bipolar
disorder–a double-blind randomized placebo-controlled trial. Biol
Psychiatry 2008, 64(6):468–75.
45. Park C, Park SK: Molecular links between mitochondrial dysfunctions and
schizophrenia. Mol Cells 2012, 33(2):105–10.
46. Anglin RE, et al: The psychiatric manifestations of mitochondrial
disorders: a case and review of the literature. J Clin Psychiatry 2012,
73(4):506–12.
47. Verge B, et al: Mitochondrial DNA (mtDNA) and schizophrenia. Eur
Psychiatry 2011, 26(1):45–56.
48. Whatley SA, Curti D, Marchbanks RM: Mitochondrial involvement in
schizophrenia and other functional psychoses. Neurochem Res 1996,
21(9):995–1004.
49. Somerville SM, Conley RR, Roberts RC: Striatal mitochondria in subjects
with chronic undifferentiated vs. chronic paranoid schizophrenia.
Synapse 2012, 66(1):29–41.
50. Somerville SM, et al: Mitochondria in the striatum of subjects with
schizophrenia: relationship to treatment response. Synapse 2011,
65(3):215–24.
51. Somerville SM, Conley RR, Roberts RC: Mitochondria in the striatum of
subjects with schizophrenia. World J Biol Psychiatry 2011, 12(1):48–56.
52. Rezin GT, et al: Mitochondrial dysfunction and psychiatric disorders.
Neurochem Res 2009, 34(6):1021–9.
53. Boskovic M, et al: Oxidative stress in schizophrenia. Curr Neuropharmacol
2011, 9(2):301–12.
54. Virit O, et al: A defect in the antioxidant defense system in schizophrenia.
Neuropsychobiology 2009, 60(2):87–93.55. Zhang XY, et al: Antioxidant enzymes and lipid peroxidation in different
forms of schizophrenia treated with typical and atypical antipsychotics.
Schizophr Res 2006, 81(2–3):291–300.
56. Rosenfeld M, et al: Perturbation in mitochondrial network dynamics and
in complex I dependent cellular respiration in schizophrenia. Biol
Psychiatry 2011, 69(10):980–8.
57. Raffa M, et al: The reduction of superoxide dismutase activity is
associated with the severity of neurological soft signs in patients with
schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39(1):52–6.
58. Medina-Hernandez V, et al: Increased lipid peroxidation and neuron
specific enolase in treatment refractory schizophrenics. J Psychiatr Res
2007, 41(8):652–8.
59. Dietrich-Muszalska A, Kontek B: Lipid peroxidation in patients with
schizophrenia. Psychiatry Clin Neurosci 2010, 64(5):469–75.
60. Zhang XY, et al: Effects of risperidone and haloperidol on superoxide
dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012,
62(5–6):1928–34.
61. Dakhale GN, et al: Supplementation of vitamin C with atypical
antipsychotics reduces oxidative stress and improves the outcome of
schizophrenia. Psychopharmacology (Berl) 2005, 182(4):494–8.
62. Berk M, et al: N-acetyl cysteine as a glutathione precursor for
schizophrenia–a double-blind, randomized, placebo-controlled trial.
Biol Psychiatry 2008, 64(5):361–8.
63. Dixon BJ, Tang J, Zhang JH: The evolution of molecular hydrogen: a
noteworthy potential therapy with clinical significance. Med Gas Res 2013,
3(1):10.
64. Ohsawa I, et al: Hydrogen acts as a therapeutic antioxidant by selectively
reducing cytotoxic oxygen radicals. Nat Med 2007, 13(6):688–94.
65. Xiao M, et al: Hydrogen-rich saline reduces airway remodeling via
inactivation of NF-kappaB in a murine model of asthma. Eur Rev Med
Pharmacol Sci 2013, 17(8):1033–43.
66. Guo Z, et al: Hydrogen-rich saline protects against ultraviolet B radiation
injury in rats. J Biomed Res 2012, 26(5):365–71.
67. Cai WW, et al: Treatment with hydrogen molecule alleviates TNFalpha-
induced cell injury in osteoblast. Mol Cell Biochem 2013, 373(1–2):1–9.
68. Kajiya M, et al: Hydrogen from intestinal bacteria is protective for
Concanavalin A-induced hepatitis. Biochem Biophys Res Commun 2009,
386(2):316–21.
69. Modabbernia A, et al: Cytokine Alterations in Bipolar Disorder: a
Meta-Analysis of 30 Studies. Biol Psychiatry 2013 [Epub ahead of print].
70. Faller S, et al: Inhaled hydrogen sulfide protects against
lipopolysaccharide-induced acute lung injury in mice. Med Gas Res 2012,
2(1):26.
71. Xie K, et al: Molecular hydrogen ameliorates lipopolysaccharide-induced
acute lung injury in mice through reducing inflammation and apoptosis.
Shock 2012, 37(5):548–55.
72. Katakura M, et al: Hydrogen-rich water inhibits glucose and alpha,beta -
dicarbonyl compound-induced reactive oxygen species production in
the SHR.Cg-Leprcp/NDmcr rat kidney. Med Gas Res 2012, 2(1):18.
73. Peters O, et al: Increased formation of reactive oxygen species after
permanent and reversible middle cerebral artery occlusion in the rat.
J Cereb Blood Flow Metab 1998, 18(2):196–205.
74. Domoki F, et al: Hydrogen is neuroprotective and preserves
cerebrovascular reactivity in asphyxiated newborn pigs. Pediatr Res 2010,
68(5):387–92.
75. Ohno K, Ito M, Ichihara M: Molecular hydrogen as an emerging
therapeutic medical gas for neurodegenerative and other diseases.
Oxid Med Cell Longev 2012:353152. Epub.
76. Ghanizadeh A: Hydrogen as a novel hypothesized emerging treatment for
oxidative stress in autism. Eur Rev Med Pharmacol Sci 2012, 16(9):1313–4.
77. Ghanizadeh A: Physical exercise and intermittent administration of
lactulose may improve autism symptoms through hydrogen production.
Med Gas Res 2012, 2(1):19.
78. Aoki K, et al: Pilot study: Effects of drinking hydrogen-rich water on
muscle fatigue caused by acute exercise in elite athletes. Med Gas Res
2012, 2(1):12.
79. Nakao A, et al: Effectiveness of hydrogen rich water on antioxidant status
of subjects with potential metabolic syndrome-an open label pilot study.
J Clin Biochem Nutr 2010, 46(2):140–9.
80. Ito M, et al: Drinking hydrogen water and intermittent hydrogen gas
exposure, but not lactulose or continuous hydrogen gas exposure,
Ghanizadeh and Berk Medical Gas Research 2013, 3:11 Page 6 of 6
http://www.medicalgasresearch.com/content/3/1/11prevent 6-hydorxydopamine-induced Parkinson’s disease in rats.
Med Gas Res 2012, 2(1):15.
81. Zhang J, et al: Effect of hydrogen gas on the survival rate of mice
following global cerebral ischemia (Shock 37(6), 645–652, 2012). Shock
2012, 38(4):444.
82. Zhan Y, et al: Hydrogen gas ameliorates oxidative stress in early brain
injury after subarachnoid hemorrhage in rats. Crit Care Med 2012,
40(4):1291–6.
83. Yoritaka A, et al: Pilot study of H(2) therapy in Parkinson’s disease:
a randomized double-blind placebo-controlled trial. Mov Disord 2013
[Epub ahead of print].
84. Shi P, Sun W: A hypothesis on chemical mechanism of the effect of
hydrogen. Med Gas Res 2012, 2(1):17.
85. Hanaoka T, et al: Molecular hydrogen protects chondrocytes from
oxidative stress and indirectly alters gene expressions through reducing
peroxynitrite derived from nitric oxide. Med Gas Res 2011, 1(1):18.
86. Ishibashi T, et al: Consumption of water containing a high concentration
of molecular hydrogen reduces oxidative stress and disease activity in
patients with rheumatoid arthritis: an open-label pilot study. Med Gas Res
2012, 2(1):27.
87. Kang KM, et al: Effects of drinking hydrogen-rich water on the quality of
life of patients treated with radiotherapy for liver tumors. Med Gas Res
2011, 1(1):11.
88. Ono H, et al: Hydrogen(H2) treatment for acute erythymatous skin
diseases. A report of 4 patients with safety data and a non-controlled
feasibility study with H2 concentration measurement on two volunteers.
Med Gas Res 2012, 2(1):14.
89. Ito M, et al: Open-label trial and randomized, double-blind, placebo-
controlled, crossover trial of hydrogen-enriched water for mitochondrial
and inflammatory myopathies. Med Gas Res 2011, 1(1):24.
90. Ohta S, Nakao A, Ohno K: The 2011 Medical Molecular Hydrogen
Symposium: An inaugural symposium of the journal Medical Gas
Research. Med Gas Res 2011, 1(1):10.
91. Ohta S: Recent progress toward hydrogen medicine: potential of
molecular hydrogen for preventive and therapeutic applications.
Curr Pharm Des 2011, 17(22):2241–52.
doi:10.1186/2045-9912-3-11
Cite this article as: Ghanizadeh and Berk: Molecular hydrogen: an
overview of its neurobiological effects and therapeutic potential for
bipolar disorder and schizophrenia. Medical Gas Research 2013 3:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
